Results 101 to 110 of about 4,245 (206)

Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists

Indian Journal of Medical and Paediatric Oncology, 2019
This editorial commentary is an expert summary of “Peptide Receptor Radionuclide Therapy (PRRT),” encompassing the essential fundamentals and salient clinical practice points, deliberated and designed in a point-wise manner with theme-based subheadings ...
Sandip Basu, Rahul Parghane, Rohit Ranade, Pradeep Thapa, Anant Ramaswamy, Vikas Ostwal, Bhawna Sirohi, Dipanjan Panda, Shailesh V Shrikhande   +8 more
doaj   +1 more source

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

, 2013
The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of metastatic disease, cytoreductive options are limited.
Krenning, Eric, Vliet, Esther, Jong, Marion, Teunissen, Jaap, Kwekkeboom, Dik, Kam, BLR   +5 more
core   +1 more source

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Frontiers in Oncology, 2019
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs ...
Pashtoon Murtaza Kasi, Catherine L. Maige, Faisal Shahjehan, Jessica M. Rodgers, Debora L. Aloszka, Ashton Ritter, Margaret L. Andrus, Jessica M. Mcmillan, Kabir Mody, Akash Sharma, Manoj K. Jain   +10 more
doaj   +1 more source

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression. [PDF]

EJNMMI Res, 2023
Jahn U, Garske-Román U, Sandström M, Lubberink M, Sundin A.   +4 more
europepmc   +1 more source

Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy

Case Reports in Dermatological Medicine
Neuroendocrine neoplasms (NENs) encompass a diverse range of biologically and behaviorally distinct epithelial malignancies that derive from neuroendocrine cells. These neoplasms are able to secrete a variety of bioactive amines or peptide hormones.
Eleanor Tung-Hahn, Ghassan El-Haddad, Jonathan Strosberg   +2 more
doaj   +1 more source

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
Ataei-Nakhaei S, Aryana K, Mostafavi SM, Kosari HM, Esmatinia M, Aghaee A.   +5 more
europepmc   +1 more source

Survival predictors of ¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). [PDF]

J Cancer Res Clin Oncol, 2022
Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT.   +9 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. [PDF]

Cancers (Basel), 2021
Jahn U, Ilan E, Sandström M, Lubberink M, Garske-Román U, Sundin A.   +5 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors

Background: Peptide Receptor Radionuclide Therapy (PRRT), a form of Radioligand Therapy (RLT), and Capecitabine/Temozolomide (CAPTEM) are cornerstones of systemic therapy for metastatic pancreatic neuroendocrine tumors (PNETs). Data regarding comparative
Chih-Yi Liao, Joseph Tobias, Xavier M. Keutgen, Rushabh Gujarathi, Sara Abou Azar   +4 more
core   +1 more source

Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids [PDF]

Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA-TATE has recently been evaluated for the treatment of meningioma patients. However, current knowledge of the underlying radiation biology is limited, in part due to the lack of appropriate in ...
Arab, Majd, Majd Arab, Sybren L. N. Maas, Maas, Sybren L.N.; id_orcid, Reuvers, Thom G.A., Vivian Grandia, Eelke M. Bos, Nonnekens, Julie; id_orcid, Brandt, Renata M.C.; id_orcid, Julie Nonnekens, Bos, Eelke M.; id_orcid, Renata M. C. Brandt, Grandia, Vivian, Thom G. A. Reuvers   +13 more
core   +1 more source